{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:13:43Z","timestamp":1791317623160,"version":"4.3.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.critrevonc.2025.104947","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T01:06:45Z","timestamp":1758589605000},"page":"104947","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Targeted doublet therapy with encorafenib and cetuximab for BRAF V600E-mutant metastatic colorectal cancer: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"216","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0384-6970","authenticated-orcid":false,"given":"Muhammad","family":"Ansab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shree","family":"Rath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiman","family":"Araib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghazal","family":"Ishaque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6360-4477","authenticated-orcid":false,"given":"Noor Ul Huda","family":"Ramzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soban Ali","family":"Qasim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim Halil","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2025.104947_bib1","doi-asserted-by":"crossref","first-page":"S214","DOI":"10.1016\/j.annonc.2021.05.052","article-title":"SO-28 effect of prior bevacizumab treatment in BRAF V600E-mutant metastatic colorectal cancer: overall survival with encorafenib + cetuximab +\/- binimetinib in BEACON CRC","volume":"32","author":"Aderka","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104947_bib2","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1158\/2159-8290.CD-20-0187","article-title":"Egfr blockade reverts resistance to krasg12c inhibition in colorectal cancer","volume":"10","author":"Amodio","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2025.104947_bib3","unstructured":"automeris.io: Computer vision assisted data extraction from charts using WebPlotDigitizer [WWW Document], n.d. URL https:\/\/automeris.io\/ (accessed 4.27.25)."},{"key":"10.1016\/j.critrevonc.2025.104947_bib4","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1002\/sim.1221","article-title":"A graphical method for exploring heterogeneity in meta-analyses: application to a meta-analysis of 65 trials","volume":"21","author":"Baujat","year":"2002","journal-title":"Stat. Med."},{"key":"10.1016\/j.critrevonc.2025.104947_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100506","article-title":"Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience","volume":"7","author":"Boccaccino","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2025.104947_bib6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up\u2606","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104947_bib7","article-title":"Meta-analysis on the risk of fatal adverse events by bevacizumab, cetuximab, and panitumumab in 31 randomized trials including 25,000 patients with colorectal carcinoma","volume":"99","author":"Chen","year":"2020","journal-title":"Med. (Baltim. )"},{"key":"10.1016\/j.critrevonc.2025.104947_bib8","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.21.02541","article-title":"BRAF-Mutated advanced colorectal cancer: a rapidly changing therapeutic landscape","author":"Ciombor","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104947_bib9","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1158\/2159-8290.CD-17-1226","article-title":"Combined BRAF, EGFR, and MEK inhibition in patients with BRAFV600E-Mutant colorectal cancer","volume":"8","author":"Corcoran","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2025.104947_bib10","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.18.02459","article-title":"Binimetinib, encorafenib, and cetuximab triplet therapy for patients with BRAF V600E\u2013mutant metastatic colorectal cancer: safety lead-in results from the phase III BEACON colorectal cancer study","volume":"37","author":"Cutsem","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104947_bib11","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2025.104947_bib12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.critrevonc.2025.104947_bib13","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1038\/sj.bjc.6606008","article-title":"Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer","volume":"103","author":"Di Fiore","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104947_bib14","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","article-title":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (Columbus): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104947_bib15","article-title":"Safety and efficacy of encorafenib\u2013cetuximab combination in BRAFV600E-mutated metastatic colorectal cancer: real-world evidence from the CONFIDENCE spanish multicenter study","volume":"5","author":"Fern\u00e1ndez-Montes","year":"2024","journal-title":"ESMO Real. World Data Digit. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104947_bib16","first-page":"195","article-title":"A new improved graphical and quantitative method for detecting bias in meta-analysis","volume":"16","author":"Furuya-Kanamori","year":"2018","journal-title":"JBI Evid. Implement"},{"key":"10.1016\/j.critrevonc.2025.104947_bib17","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/00401706.1988.10488400","article-title":"Graphical display of estimates having differing standard errors","volume":"30","author":"Galbraith","year":"1988","journal-title":"Technometrics"},{"key":"10.1016\/j.critrevonc.2025.104947_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103696","article-title":"Efficacy and safety of the combination of encorafenib\/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter study","volume":"9","author":"Gallois","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2025.104947_bib19","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1158\/2159-8290.CD-16-0795","article-title":"A phase ib dose-escalation study of encorafenib and cetuximab with or without alpelisib in metastatic BRAF-mutant colorectal cancer","volume":"7","author":"Geel","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2025.104947_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102996","article-title":"Treatment of patients with BRAFV600E-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset","volume":"9","author":"Germani","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2025.104947_bib21","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ejca.2019.07.016","article-title":"Adverse events associated with encorafenib plus binimetinib in the Columbus study: incidence, course and management","volume":"119","author":"Gogas","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104947_bib22","article-title":"Targeting BRAF V600E in metastatic colorectal cancer: where are we today?","author":"Guerrero","year":"2022","journal-title":"[WWW Doc. ]"},{"key":"10.1016\/j.critrevonc.2025.104947_bib23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med. Res. Method."},{"key":"10.1016\/j.critrevonc.2025.104947_bib24","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2217\/fon-2019-0748","article-title":"Encorafenib, binimetinib and cetuximab combined therapy for patients with BRAFV600E mutant metastatic colorectal cancer","volume":"16","author":"Huijberts","year":"2020","journal-title":"Future Oncol."},{"key":"10.1016\/j.critrevonc.2025.104947_bib25","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1200\/JCO.2015.63.2497","article-title":"Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer","volume":"33","author":"Kopetz","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104947_bib26","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E\u2013Mutated colorectal cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104947_bib27","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/s41591-024-03443-3","article-title":"Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial","volume":"31","author":"Kopetz","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2025.104947_bib28","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.4_suppl.16","article-title":"BREAKWATER: analysis of first-line encorafenib + cetuximab + chemotherapy in BRAF V600E-mutant metastatic colorectal cancer","volume":"43","author":"Kopetz","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104947_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179691","article-title":"Evaluation of molecular diagnostic approaches for the detection of BRAF p.V600E mutations in papillary thyroid cancer: clinical implications","volume":"12","author":"Kowalik","year":"2017","journal-title":"PLOS ONE"},{"key":"10.1016\/j.critrevonc.2025.104947_bib30","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2013.08.024","article-title":"FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer","volume":"50","author":"Loupakis","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104947_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100603","article-title":"Real-world first-line treatment of patients with BRAFV600E-mutant metastatic colorectal cancer: the CAPSTAN CRC study\u2606","volume":"7","author":"Martinelli","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2025.104947_bib32","unstructured":"Ottawa Hospital Research Institute [WWW Document], n.d. URL https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp (accessed 4.27.25)."},{"key":"10.1016\/j.critrevonc.2025.104947_bib33","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2025.104947_bib34","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S1470-2045(17)30679-4","article-title":"Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial","volume":"18","author":"Planchard","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104947_bib35","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","article-title":"Trifluridine\u2013Tipiracil and bevacizumab in refractory metastatic colorectal cancer","volume":"388","author":"Prager","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104947_bib36","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature10868","article-title":"Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR","volume":"483","author":"Prahallad","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2025.104947_bib37","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","author":"Sterne","year":"2019","journal-title":"BMJ 366"},{"key":"10.1016\/j.critrevonc.2025.104947_bib38","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1200\/JCO.22.01420","article-title":"FOLFOXIRI plus cetuximab or bevacizumab as First-Line treatment of brafV600E -Mutant metastatic colorectal cancer: the randomized phase II FIRE-4.5 (AIO KRK0116) study","volume":"41","author":"Stintzing","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104947_bib39","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"Ca. Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2025.104947_bib40","doi-asserted-by":"crossref","first-page":"5748","DOI":"10.3390\/cancers15245748","article-title":"The impact of BRAF mutation status on survival outcomes and treatment patterns among metastatic colorectal cancer patients in alberta, Canada","volume":"15","author":"Sutherland","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2025.104947_bib41","doi-asserted-by":"crossref","first-page":"ii127","DOI":"10.1093\/annonc\/mdw198.25","article-title":"O-026 combination of encorafenib and cetuximab with or without alpelisib in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC): phase 2 results","volume":"27","author":"Tabernero","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104947_bib42","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.20.02088","article-title":"Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E\u2013Mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study","volume":"39","author":"Tabernero","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104947_bib43","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1200\/EDBK_349561","article-title":"The evolving treatment landscape in braf-v600e \u2013Mutated metastatic colorectal cancer","author":"Tabernero","year":"2022","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.critrevonc.2025.104947_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100328","article-title":"Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study","volume":"6","author":"Tabernero","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2025.104947_bib45","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1002\/ijc.25555","article-title":"Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAFV600E mutation","volume":"128","author":"Tie","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104947_bib46","article-title":"Encorafenib and cetuximab versus irinotecan\/cetuximab or FOLFIRI\/cetuximab in Chinese patients with BRAF V600E mutant metastatic colorectal cancer: the NAUTICAL CRC study","volume":"42","author":"Wang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104947_bib47","doi-asserted-by":"crossref","first-page":"10473","DOI":"10.1002\/cam4.5783","article-title":"Real-world treatment and outcomes of patients with metastatic BRAF mutant colorectal cancer","volume":"12","author":"Xu","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.critrevonc.2025.104947_bib48","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1158\/1078-0432.CCR-14-2779","article-title":"Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients","volume":"21","author":"Yaeger","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104947_bib49","doi-asserted-by":"crossref","first-page":"6513","DOI":"10.1158\/0008-5472.CAN-17-0768","article-title":"Mechanisms of acquired resistance to BRAF V600E inhibition in colon cancers converge on RAF dimerization and are sensitive to its inhibition","volume":"77","author":"Yaeger","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2025.104947_bib50","first-page":"110","article-title":"Efficacy-effectiveness analysis on survival in a population-based real-world study of BRAF-mutated metastatic colorectal cancer patients treated with encorafenib-cetuximab","volume":"131","author":"Zwart","year":"2024","journal-title":"Br. J. Cancer 2024 1311"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282500335X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282500335X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T21:13:27Z","timestamp":1767388407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104084282500335X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":50,"alternative-id":["S104084282500335X"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104947","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted doublet therapy with encorafenib and cetuximab for BRAF V600E-mutant metastatic colorectal cancer: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104947","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104947"}}